BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 8442109)

  • 1. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
    Mrsić M; Nemet D; Labar B; Bogdanić V; Radman I; Zupancić-Salek S; Kovacević-Metelko J; Aurer I; Maravić N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1268-70. PubMed ID: 8442109
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful bone marrow transplant for a patient with T-lymphoblastic lymphoma in second remission preconditioned by total-body irradiation plus melphalan and etoposide.
    Nomura N; Uchida H; Nakamura H; Shirota T; Sakai N; Ito H; Suzuki A; Otaka M; Kimura Y; Toyama K
    Transplant Proc; 1994 Aug; 26(4):2347. PubMed ID: 8066769
    [No Abstract]   [Full Text] [Related]  

  • 3. Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
    Russell S; Vowels M
    Transplant Proc; 1992 Feb; 24(1):183. PubMed ID: 1539236
    [No Abstract]   [Full Text] [Related]  

  • 4. Autologous and allogeneic bone marrow transplantation for childhood acute nonlymphoblastic leukemia.
    Vowels M; Stevens M; Tiedemann K; Brown R
    Transplant Proc; 1992 Feb; 24(1):184-5. PubMed ID: 1539237
    [No Abstract]   [Full Text] [Related]  

  • 5. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic BMT versus autologous BMT in childhood acute lymphoblastic leukemia (ALL): an Italian cooperative study of vincristine (VCR), F-TBI and cyclophosphamide. AIEOP (Associazione Italiana Ematologia ed Oncologia Pediatrica) Italy.
    Uderzo C; Coleselli P; Messina C; Dini G; Bonetti F; Andolina M; Bagnulo S; Miniero R; Rondelli R; Paolucci P
    Bone Marrow Transplant; 1991; 7 Suppl 2():132. PubMed ID: 1878677
    [No Abstract]   [Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T; Kojima S; Kato K
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
    Przepiorka D; Giralt S; Huh YO; Andreeff M; Luna M; Reading C; Thomas M; Champlin RE
    Transplant Proc; 1992 Dec; 24(6):2906-7. PubMed ID: 1465994
    [No Abstract]   [Full Text] [Related]  

  • 10. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan and cyclophosphamide as conditioning regimen for autologous BMT in acute lymphoblastic leukemia.
    Porcellini A; Manna A; Moretti L; Carotenuto M; Greco MM; Bodenizza C
    Bone Marrow Transplant; 1989 May; 4(3):331-3. PubMed ID: 2659120
    [No Abstract]   [Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle.
    von Bueltzingsloewen A; Esperou-Bourdeau H; Souillet G; Demeocq F; Mechinaud-Lacroix F; Michel G; Sadoun A; Bernaudin F; Cornu G; Donadieu J
    Bone Marrow Transplant; 1995 Oct; 16(4):521-7. PubMed ID: 8528167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
    Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
    Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
    Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
    Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation for acute lymphoblastic leukaemia in first and second remission.
    Barrett AJ; Horowitz MM; McCarthy DM; Kanfer E; Bortin MM
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():247-9. PubMed ID: 2653514
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
    Copelan EA; Biggs JC; Avalos BR; Szer J; Cunningham I; Klein JP; Atkinson K; Kapoor N; Klein JL; Downs K
    J Clin Oncol; 1992 Feb; 10(2):237-42. PubMed ID: 1732424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.